4D Molecular Therapeutics (FDMT) Operating Expenses (2020 - 2026)

4D Molecular Therapeutics (FDMT) has 7 years of Operating Expenses data on file, last reported at $76.7 million in Q1 2026.

• Operating Expenses for Q1 2026 came in at $76.7 million, up 42.94% year-over-year; the trailing twelve-month figure through Mar 2026 was $267.8 million (up 31.69% YoY), and the FY2025 annual result was $244.8 million, up 30.27% from the prior year.
• Operating Expenses advanced to $76.7 million in Q1 2026 per FDMT's latest filing, from $70.4 million in the prior quarter.
• Over five years, Operating Expenses peaked at $76.7 million in Q1 2026 and troughed at $27.0 million in Q3 2022.
• A 5-year average of $44.5 million and a median of $38.2 million in 2024 frame the typical range for Operating Expenses.
• The sharpest annual moves came in 2023 and 2024: Operating Expenses rose 10.12% in 2023, then surged 53.19% in 2024.
• A 5-year view of Operating Expenses shows it stood at $30.0 million in 2022, then increased by 22.24% to $36.6 million in 2023, then surged by 53.19% to $56.1 million in 2024, then gained by 25.41% to $70.4 million in 2025, then climbed by 8.94% to $76.7 million in 2026.
• Business Quant data shows FDMT's Operating Expenses at $76.7 million in Q1 2026, $70.4 million in Q4 2025, and $61.3 million in Q3 2025.